These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33631988)

  • 1. Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use.
    Hey A; Baumann A; Kronenberg S; Blaich G; Mohl S; Fagg R; Ulrich P; Rattel B; Richter WF; Kiessling A; Weir L
    Int J Toxicol; 2021; 40(3):270-284. PubMed ID: 33631988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New challenges and opportunities in nonclinical safety testing of biologics.
    Baumann A; Flagella K; Forster R; de Haan L; Kronenberg S; Locher M; Richter WF; Theil FP; Todd M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):226-33. PubMed ID: 24755365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.
    Blaich G; Baumann A; Kronenberg S; de Haan L; Ulrich P; Richter WF; Tibbitts J; Chivers S; Tarcsa E; Caldwell R; Crameri F
    Regul Toxicol Pharmacol; 2016 Oct; 80S():S1-S14. PubMed ID: 27578450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.
    Ulrich P; Blaich G; Baumann A; Fagg R; Hey A; Kiessling A; Kronenberg S; Lindecrona RH; Mohl S; Richter WF; Tibbitts J; Crameri F; Weir L
    Regul Toxicol Pharmacol; 2018 Apr; 94():91-100. PubMed ID: 29355662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting.
    Kissner T; Blaich G; Baumann A; Kronenberg S; Hey A; Kiessling A; Schmitt PM; Driessen W; Carrez C; Kramer D; Fretland J; Richter WF; Paehler T; Hopfer U; Rattel B
    MAbs; 2021; 13(1):1938796. PubMed ID: 34241561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current challenges and opportunities in nonclinical safety testing of biologics.
    Kronenberg S; Baumann A; de Haan L; Hinton HJ; Moggs J; Theil FP; Wakefield I; Singer T
    Drug Discov Today; 2013 Dec; 18(23-24):1138-43. PubMed ID: 23942260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.
    Brennan FR; Baumann A; Blaich G; de Haan L; Fagg R; Kiessling A; Kronenberg S; Locher M; Milton M; Tibbitts J; Ulrich P; Weir L
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):265-75. PubMed ID: 26219199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.
    Sewell F; Chapman K; Couch J; Dempster M; Heidel S; Loberg L; Maier C; Maclachlan TK; Todd M; van der Laan JW
    MAbs; 2017 Jul; 9(5):742-755. PubMed ID: 28475417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
    Agoram BM
    Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.
    Vugmeyster Y; Xu X; Theil FP; Khawli LA; Leach MW
    World J Biol Chem; 2012 Apr; 3(4):73-92. PubMed ID: 22558487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.
    Ménochet K; Yu H; Wang B; Tibbitts J; Hsu CP; Kamath AV; Richter WF; Baumann A
    MAbs; 2022; 14(1):2145997. PubMed ID: 36418217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
    Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B
    Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
    van Meer PJ; Kooijman M; Brinks V; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    MAbs; 2013; 5(5):810-6. PubMed ID: 23924803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.